The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 24, 1995

Filed:

Mar. 07, 1994
Applicant:
Inventor:

Richard G Olsen, London, OH (US);

Assignee:

Parhelion Corporation, Columbus, OH (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K / ; C12N / ; C12N / ; C12N / ;
U.S. Cl.
CPC ...
424221 ; 4352351 ; 4352402 ;
Abstract

One aspect of the present invention comprises a vaccine for the prevention of disease caused by feline infectious peritonitis virus (FIPV). Such vaccine comprises FIP viral precursor immunogens derived from in vitro produced cells persistently infected with FIPV. Preferred in the production of viral immunogens forming the vaccine of the present invention is the Crandall Feline Kidney (CrFK) cell line. Thus, a second aspect of the invention comprises FIP-infected Crandall Feline Kidney cell line, deposited at the American Type Culture Collection (ATCC), Rockville, MD, on Sep. 23, 1992, and granted Accession No. CRL11137. A third aspect of the invention relates to a method of producing FIP viral precursor immunogens, which comprises culturing in vitro FIP-persistent infected cells in a serum-containing growth medium, subsequently transferring and maintaining said cultured cells in a serum-free medium under conditions and for a time adequate to accumulate FIP viral precursor immunogens shed from said cells, and then separating the cells from the supernatant containing the vital precursor immunogens. The supernatant containing the FIP viral precursor immunogens is blended with a pharmaceutically-acceptable adjuvant in order to form the FIP vaccine disclosed herein.


Find Patent Forward Citations

Loading…